Evidence map›Paper›PMID 38007476›Full record

ReviewCell death & disease2023

Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma.

Tiantian Yu, Zijun Y Xu-Monette, Li Yu, Yong Li, Ken H Young

Erratum issuedAbstract readReview
In one paragraph

Review in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Tiantian YuHematopathology Division and Department of Pathology, Duke University Medical Center, Durham, NC, USA.
Zijun Y Xu-MonetteHematopathology Division and Department of Pathology, Duke University Medical Center, Durham, NC, USA.
Li YuDepartment of Hematology and Oncology, The Second Affiliated Hospital of NanChang University, Nanchang, China.
Yong LiDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-8838-1714
Ken H YoungHematopathology Division and Department of Pathology, Duke University Medical Center, Durham, NC, USA. ken.young@duke.edu.ORCID 0000-0002-5755-8932

Funding

Prevention of MGUS Progression to MM by Modulating the Bone Marrow MicroenvironmentU54CA272691 · NCI · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · PI John Damian Shaughnessy · 2023 to 2026
$6.1M
Genetic and Epigenetic Biomarkers for B-cell LymphomaR01CA233490 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YOUNG, KEN H. · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA233490NCI NIH HHS U54 CA272691
6 · The paper itself

Abstract

Lymphoma is the sixth most common type of cancer worldwide. Under the current treatment standards, patients with lymphoma often fail to respond to treatment or relapse early and require further therapy. Hence, novel therapeutic strategies need to be explored and our understanding of the molecular underpinnings of lymphomas should be expanded. Ferroptosis, a non-apoptotic regulated cell death, is characterized by increased reactive oxygen species and lipid peroxidation due to metabolic dysfunction. Excessive or lack of ferroptosis has been implicated in tumor development. Current preclinical evidences suggest that ferroptosis participates in tumorigenesis, progression, and drug resistance of lymphoma, identifying a potential biomarker and an attractive molecular target. Our review summarizes the core mechanisms and regulatory networks of ferroptosis and discusses existing evidences of ferroptosis induction for the treatment of lymphoma, with intent to provide a framework for understanding the role of ferroptosis in lymphomagenesis and a new perspective of lymphoma treatment.

Indexed as

FerroptosisLymphomaRegulated Cell DeathCarcinogenesisCell Transformation, NeoplasticHumansLipid Peroxidation

Identifiers

PMID38007476
PMCPMC10676406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.